These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25986996)

  • 61. Bevacizumab and hereditary haemorrhagic telangiectasia.
    Cruikshank RP; Chern BW
    Med J Aust; 2011 Mar; 194(6):324-5. PubMed ID: 21426291
    [No Abstract]   [Full Text] [Related]  

  • 62. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
    Arizmendez NP; Rudmik L; Poetker DM
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy.
    Albitar HAH; Almodallal Y; Gallo De Moraes A; O'Brien E; Choby GW; Pruthi RK; Stokken JK; Kamath PS; Cajigas HR; DuBrock HM; Krowka MJ; Iyer VN
    Mayo Clin Proc; 2020 Aug; 95(8):1604-1612. PubMed ID: 32753135
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hereditary Hemorrhagic Telangiectasia Management.
    Peterson J
    Radiol Technol; 2017 Jan; 88(3):277-294. PubMed ID: 28298578
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Diagnosis and treatment of morbus Osler].
    Kjeldsen AD; Andersen PE; Tørring PM
    Ugeskr Laeger; 2011 Feb; 173(7):490-5. PubMed ID: 21320413
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Plasma VEGF - a candidate biomarker for response to treatment with bevacizumab in HHT patients.
    Liu DT; Frohne A; Koenighofer M; Frei K; Lucas T; Riss D; Parzefall T
    Rhinology; 2020 Feb; 58(1):18-24. PubMed ID: 31681913
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
    Alderman C; Corlett J; Cullis J
    Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
    [No Abstract]   [Full Text] [Related]  

  • 68. [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].
    Morales-Angulo C; Pérez del Molino A; Zarrabeitia R; Fernández A; Sanz-Rodríguez F; Botella LM
    Acta Otorrinolaringol Esp; 2007 Apr; 58(4):129-32. PubMed ID: 17428407
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study.
    Dheyauldeen S; Abdelnoor M; Bachmann-Harildstad G
    Am J Rhinol Allergy; 2011; 25(4):214-8. PubMed ID: 21819756
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey.
    Zaffar N; Ravichakaravarthy T; Faughnan ME; Shehata N
    Ann Hematol; 2015 Jan; 94(1):145-52. PubMed ID: 25064693
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds.
    Pagella F; Matti E; Chu F; Pusateri A; Tinelli C; Olivieri C; Canzonieri C; Boeri L; Ornati F; Danesino C
    Acta Otolaryngol; 2013 Feb; 133(2):174-80. PubMed ID: 23066781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study.
    de Gussem EM; Snijder RJ; Disch FJ; Zanen P; Westermann CJ; Mager JJ
    Rhinology; 2009 Mar; 47(1):85-8. PubMed ID: 19382502
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization.
    Trojanowski P; Jargiello T; Trojanowska A; Klatka J
    Acta Radiol; 2011 Oct; 52(8):846-9. PubMed ID: 21816895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia.
    Kjeldsen AD; Møller TR; Brusgaard K; Vase P; Andersen PE
    J Intern Med; 2005 Oct; 258(4):349-55. PubMed ID: 16164574
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of Hereditary Haemorrhagic Telangiectasia with Bevacizumab - What More Needs to be Known?
    Morrissey E; Schmidt-Martin D; Buckley M
    Eur J Case Rep Intern Med; 2024; 11(1):004219. PubMed ID: 38223286
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of anterior palatine blocks on bleeding in hereditary hemorrhagic telangiectasia nasal surgery.
    Guthrie CC; Karnezis TT; Orosco RK; Bishop ML; Davidson TM
    Laryngoscope; 2013 Nov; 123(11):2598-600. PubMed ID: 23670536
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia.
    Kovacs-Sipos E; Holzmann D; Scherer T; Soyka MB
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28652319
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
    Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L
    Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.